<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529490</url>
  </required_header>
  <id_info>
    <org_study_id>001/CT-KB/DNA/02</org_study_id>
    <nct_id>NCT00529490</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats</brief_title>
  <official_title>The Efficacy and Safety of Hypertonic Lactate Solution as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG (Coronary Artery Bypass Grafting) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innogene Kalbiotech Pte. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, open-label study to assess the efficacy and safety of hypertonic
      lactate solution, compared to Ringer's Lactate as fluid resuscitation to maintain hemodynamic
      stability in post-coronary artery bypass grafting(CABG) patients. Patients who were eligible
      received either hypertonic lactate solution or Ringer's Lactate post-CABG in the ICU when
      fluid resuscitation was needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, open-label study to assess the efficacy and safety of hypertonic
      lactate solution, compared to Ringer's Lactate as fluid resuscitation to maintain hemodynamic
      stability in post-coronary artery bypass grafting(CABG) patients. Patients who were eligible
      received either hypertonic lactate solution or Ringer's Lactate post-CABG observed in the
      first 12 hours in the ICU when fluid resuscitation was needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemodynamic stability</measure>
    <time_frame>12 hours post-CABG surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of hypertonic sodium lactate for maintaining the hemodynamic stability</measure>
    <time_frame>12 hours post-CABG surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Low Cardiac Output</condition>
  <arm_group>
    <arm_group_label>HL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic lactate group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ringer's lactate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic lactate</intervention_name>
    <description>Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG</description>
    <arm_group_label>HL</arm_group_label>
    <other_name>Totilac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's lactate</intervention_name>
    <description>Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG</description>
    <arm_group_label>RL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given their written informed consent.

          -  Male or female, aged 18-75 years.

          -  Post-operative CABG on pump or off pump in ICU.

          -  Patients who need fluid resuscitation.

        Exclusion Criteria:

          -  Combined operations.

          -  Need for intra aortic balloon pump (IABP).

          -  Patients with severe arrhythmia (VT, AF rapid response, heart block).

          -  Severe hemodynamic imbalance.

          -  Severe bleeding and/or re-operation.

          -  Liver dysfunction(SGOT and SGPT 2x normal).

          -  Renal failure (Creatinine &gt;2 mg%).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iqbal Mustafa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National cardiac Centre, Harapan Kita Hospital, Dept. of Anaesthesiology, Intensive Care Unit, Jakarta, Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Leverve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, INSERM-E0221-Bioenergetique Fondamentale et Appliquée Université, Joseph Fourier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>September 12, 2007</last_update_submitted>
  <last_update_submitted_qc>September 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2007</last_update_posted>
  <keyword>coronary</keyword>
  <keyword>artery</keyword>
  <keyword>bypass</keyword>
  <keyword>grafting</keyword>
  <keyword>I.V.</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

